# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and maintains $10 price target.
Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and maintains $1.25 price target.
In addition, Seres is due to receive installment payments in 2025, as well as potential future payments based on VOWST net sale...
Oppenheimer analyst Jeff Jones downgrades Seres Therapeutics (NASDAQ:MCRB) from Outperform to Perform.